Bio-Rad Laboratories, Inc.
Bio-Rad Laboratories, Inc.
Bio-Rad Laboratories, Inc.
BIO
BIO
NYSE
Health Technology
Medical Specialties
305.96
USD
+4.26
+1.41%
Fechado: 07-22 20:00 (UTC+0)
305.96
USD
+1.34
+0.44%
Pré-mercado: 07-23 08:26 (UTC+0)

BIO Estatísticas principais

Alta
307.10
Abrir
301.00
Volume
275.06K
Baixa
298.74
Fechamento anterior
301.70
Valor negociado
84.03M
52 sem. máx.
343.12
Vol. relativo
0.897
Amplitude (%)
2.77%
52 sem. mín.
236.73
Taxa de giro
1.27%
Cap. de Mercado
8.18B
P/L (TTM)
50.37
P/L (Anual)
10.978
P/VP
1.2
P/S
3.16
Lucro por ação (EPS)
6.075
Dividendo (TTM)
0
Rendimento de dividendos
0.00%
Ações em circulação
21.70M
Unidade monetária
USD

BIO Desempenho de Preço

7 dia
30 dia
90 dia
180 dia
No acumulado do ano
1 Ano
BIO Distribuição do fluxo de dinheiro
BIO Volume diário de venda a descoberto
BIO Histórico de short interest
As of 2026-07-23, the Bio-Rad Laboratories, Inc. (BIO) stock price today is 305.96. Based on this price, the company has a market capitalization of $8.18B, with a P/E ratio of 50.37. On 2026-07-23, BIO traded between 298.74 and 307.10. Today’s stock price is 2.42% above the daily low and 0.37% below the daily high, placing BIO perto da extremidade superior de its most recent trading range. Trading volume currently stands at 275.06K, compared with an average daily volume of 306.76K. This suggests that trading activity is aproximadamente em linha com o nível habitual than usual. Over the past year, Bio-Rad Laboratories, Inc. shares have traded between 236.73 and 343.12. At today’s price, BIO is 29.24% above its 52-week low and 10.83% below its 52-week high.
Nome empresa
Bio-Rad Laboratories, Inc.
Setor
Health Technology
Indústria
Medical Specialties
Trocas
NYSE
Número de funcionários
7,450
Tamanho do lote
40
Site oficial
Unidade monetária
USD
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.

BIO FAQ

Pesquisar
Mais